Resveratrol inhibits periodontitis-related bone loss in rats. - GreenMedInfo Summary
Resveratrol Inhibits Periodontitis-Related Bone Loss in Rats Submitted to Cigarette Smoke Inhalation.
J Periodontol. 2017 May 11:1-16. Epub 2017 May 11. PMID: 28492360
Fernanda V Ribeiro
BACKGROUND: Alternative therapeutic approaches have been explored in order to modulate the host's response to periodontal disease. The knowledge of new strategies to treat periodontitis is particularly relevant in patients presenting augmented risk to periodontitis, as smokers. The aim of this study was to investigate the impact of Resveratrol (RESV) on the progression of experimental periodontitis (EP) in the presence of cigarette smoke inhalation (CSI).
METHODS: Rats were assigned to: CSI+RESV(n=20); CSI+placebo(n=20); Non-CSI(n=20). CSI was initiated one week prior to initiation of RESV or placebo administration (systemically for 30 days) and was performed until the end of study. EP was induced about the first mandibular and the second maxillary molar using ligatures. The specimens from the mandible were processed for morphometric and micro-CT examination of bone volume/levels. Gingival tissues surrounding the mandibular molars were collected for quantification of interleukin (IL)-1β, IL-4, IL-6, IL-17 and tumor necrosis factor (TNF)-α using a Luminex/MAGpix assay. Additional analyses of immune-inflammatory mediator's performance (Th-17/Th-2 and Th1/Th2 levels) were performed according to T-helper responses in gingival tissues. Gingival tissue of maxillary molars was subjected to RT-PCR for assessment of Osteoprotegrin (OPG), Runted-related transcription factor-2 (Runx2), receptor activator of NF-КB ligand (RANKL), Sclerostin (Sost), and Dickkopf Wnt signaling pathway inhibitor 1 (Dkk1) levels.
RESULTS: Higher linear bone loss and lower interradicular bone density were detected in ligated molars in the CSI+placebo (p<0.05). In RESV-treated rats, IL-4 was the highest while levels of Th17/Th2 levels were the lowest in comparison to placebo rats (p<0.05). RESV reduced expression of mRNA for RANKL in animals receiving CSI (p<0.05).
CONCLUSION: RESV inhibits EP and CSI-induced loss of supporting alveolar bone and has a beneficial effect on osteo-immune-inflammatory markers.